High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Looking back at past stock picks is important because it helps investors understand what worked, what didn’t, and why. The insurance stock is down 19% over the past year but has gained 8% over the past month.
(Bloomberg) -- At the Hirslanden clinic overlooking Switzerland’s picturesque Lake Lucerne, prostate cancer patient Jörg Pegelow lies on a reclining chair as a doctor wearing two sets of gloves — one made with lead — injects a saline solution laced with a radioactive drug into a vein in his arm.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapOracle Cut 21,000 Jobs in 12 Months, Says AI Replaced
At 64, with $1.1 million in a Traditional IRA, tax-deferred cash flow is the point. With the 10-year Treasury at 4.50% and the 30-year at 4.94%, dividend yields have to earn their seat. The 10-year has swung between 4.43% and 4.56% in June alone, and that yield volatility is exactly what forced me to re-stack ... 64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital
Bristol Myers Squibb’s board previously declared a quarterly dividend of US$0.63 per share on its common stock, payable on August 3, 2026, to shareholders of record as of July 2, 2026. This dividend decision comes as the company works to address upcoming patent expirations by advancing a broad pipeline that includes 50 compounds and multiple new medicines targeted for launch by 2030. We’ll now examine how this affirmed dividend, alongside Bristol Myers Squibb’s expanding pipeline, shapes the...
The latest trading day saw Bristol Myers Squibb (BMY) settling at $55.53, representing a +1.52% change from its previous close.
Bristol-Myers Squibb Company (NYSE:BMY) is among the Best Pharmaceutical Stocks. On June 2, Bristol-Myers Squibb Company (NYSE:BMY) and SystImmune announced that SystImmune’s parent company, Sichuan Biokin Pharmaceutical, reported interim Phase 3 data. It showed that izalontamab brengitecan had statistically significant progress in overall survival and progression-free survival in advanced triple-negative breast cancer and esophageal squamous […]
CEO Tassos Gianakakos said having late-stage assets and a team fortified at MyoKardia really resonated with investors. SpaceX's huge public offering didn't hurt either.
Fears about a looming patent cliff have dragged on the shares.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
RLTs were a hot topic at ASCO 2026, but experts note that certain limitations must be addressed to facilitate their widespread use in cancer care.
Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts and newer medicines can keep the 2026 earnings outlook on track.
Investing.com -- Kardigan Inc. shares rose iver 27% roughly one hour into its Nasdaq debut on Thursday, after the heart-health focused biotech raised $400 million in an initial public offering.
Bristol-Myers Squibb (BMY) stock is drawing attention after recent trading performance, with shares closing at US$55.28. Investors are weighing this level against the company’s mixed growth profile across revenue, earnings and longer term returns. See our latest analysis for Bristol-Myers Squibb. Recent trading has been a bit soft, with a 30 day share price return down 3.54% and a 90 day return down 4.87%. However, the 1 year total shareholder return of 23.92% shows that longer term holders...
Bristol Myers Squibb (NYSE:BMY) reported positive Phase III SUCCESSOR-2 trial results in multiple myeloma at a major medical conference. The company highlighted early clinical success for a new CAR T-cell therapy targeting blood cancers. Bristol Myers Squibb appointed a new General Manager to lead its operations across the Gulf region. Bristol Myers Squibb is a large biopharmaceutical company with a long-standing focus on oncology and hematology treatments. The fresh readout from the...
The latest trading day saw Bristol Myers Squibb (BMY) settling at $55.28, representing a -1.14% change from its previous close.
CYTK has gained 18.4% YTD as Myqorzo's FDA approval, early launch momentum, and expanding market opportunities fuel investor interest.
IMCR is seeing strong Kimmtrak sales growth and pursuing label expansion studies that could broaden its reach across melanoma treatments.
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Bristol Myers Squibb (BMS) has revealed clinical data for two pipeline candidates in multiple myeloma (MM) at the European Hematology Association Congress (EHA) 2026, held from June 11–14. While the drugmaker already has multiple therapies approved for the type of blood cancer, BMS is hoping to expand its presence in the market by addressing certain…
Bristol Myers eyes growth from Camzyos as the FDA reviews its use in adolescents with obstructive HCM, expanding the drug's market reach.
Edgewise Therapeutics shares yo-yoed Tuesday as investors compared the results of its experimental heart disease treatment to approved drugs.
They have a habit of consistently raising their payouts.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
